SG11201507470WA - Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions - Google Patents
Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditionsInfo
- Publication number
- SG11201507470WA SG11201507470WA SG11201507470WA SG11201507470WA SG11201507470WA SG 11201507470W A SG11201507470W A SG 11201507470WA SG 11201507470W A SG11201507470W A SG 11201507470WA SG 11201507470W A SG11201507470W A SG 11201507470WA SG 11201507470W A SG11201507470W A SG 11201507470WA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor
- treatment
- conditions
- mediated diseases
- selective agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793736P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/029057 WO2014144584A2 (en) | 2013-03-15 | 2014-03-14 | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507470WA true SG11201507470WA (en) | 2015-10-29 |
Family
ID=50897877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507470WA SG11201507470WA (en) | 2013-03-15 | 2014-03-14 | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9688627B2 (zh) |
| EP (2) | EP2989098B1 (zh) |
| JP (2) | JP6317807B2 (zh) |
| KR (1) | KR20150130326A (zh) |
| CN (1) | CN105143217A (zh) |
| AU (1) | AU2014228973B2 (zh) |
| BR (1) | BR112015023080A2 (zh) |
| CA (1) | CA2906134A1 (zh) |
| DK (1) | DK2989098T3 (zh) |
| EA (1) | EA201591793A1 (zh) |
| ES (1) | ES2635635T3 (zh) |
| HK (1) | HK1222170A1 (zh) |
| IL (2) | IL240988A (zh) |
| PH (1) | PH12015502165A1 (zh) |
| PT (1) | PT2989098T (zh) |
| SG (1) | SG11201507470WA (zh) |
| WO (1) | WO2014144584A2 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107802623B (zh) | 2012-07-19 | 2020-10-30 | 开曼化学股份有限公司 | 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物 |
| CA2910398A1 (en) | 2013-07-19 | 2015-01-22 | Cayman Chemical Company, Inc. | Methods, systems, and compositions for promoting bone growth |
| CN107365329B (zh) * | 2016-05-12 | 2019-02-01 | 华东师范大学 | 一种3-甲基-2-氧代-5-庚炔基磷酸二甲酯的制备方法 |
| CN111511736B (zh) | 2017-12-25 | 2023-03-24 | 旭化成制药株式会社 | 含氮6元环化合物 |
| BR112021019465A8 (pt) | 2019-04-02 | 2022-06-07 | Aligos Therapeutics Inc | Compostos que têm como alvo prmt5 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
| DE2517771A1 (de) | 1975-04-18 | 1976-10-28 | Schering Ag | Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung |
| CA1085859A (en) | 1975-06-27 | 1980-09-16 | Wilhelm Bartmann | Pyrrolidones and process for their manufacture |
| DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4268522A (en) | 1976-06-14 | 1981-05-19 | Pfizer Inc. | 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof |
| US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
| US6043275A (en) | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
| US6894175B1 (en) | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
| TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| BR0016560A (pt) | 1999-12-22 | 2002-09-10 | Pfizer Prod Inc | Agonistas seletivos do receptor ep4 no tratamento da osteoporose |
| US20010056060A1 (en) | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| AU2001290250A1 (en) | 2000-09-21 | 2002-04-02 | Ono Pharmaceutical Co. Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| KR20030053063A (ko) * | 2000-11-27 | 2003-06-27 | 화이자 프로덕츠 인코포레이티드 | 골다공증 치료용 이피4 수용체 선택성 작용제 |
| AU2002328855B2 (en) | 2001-07-16 | 2005-11-24 | F. Hoffmann-La Roche Ag | Prostaglandin Analogues As EP4 Receptor Agonists |
| DE60221130T2 (de) | 2001-07-16 | 2008-03-13 | F. Hoffmann-La Roche Ag | 2 pyrrolidon-derivate als prostanoid-agonisten |
| KR20070043059A (ko) | 2001-07-23 | 2007-04-24 | 오노 야꾸힝 고교 가부시키가이샤 | Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하 질환의치료제 |
| IL161581A0 (en) | 2001-10-23 | 2004-09-27 | Applied Research Systems | Pyrazolidinone derivatives and their use |
| AU2002346561B2 (en) | 2001-12-03 | 2006-08-17 | Merck & Co., Inc. | EP4 receptor agonist, compositions and methods thereof |
| EP1461026A2 (en) | 2001-12-03 | 2004-09-29 | Merck & Co., Inc. | Method for treating ocular hypertension |
| CN1653046A (zh) | 2002-03-05 | 2005-08-10 | 小野药品工业株式会社 | 8－氮杂前列腺素衍生化合物以及包含该化合物作为活性成分的药物 |
| MXPA04009036A (es) | 2002-03-18 | 2005-01-25 | Pfizer Prod Inc | Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular. |
| CA2478653A1 (en) | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| WO2003103604A2 (en) * | 2002-06-01 | 2003-12-18 | Applied Research Systems Ars Holding N.V | Gamma lactams as prostaglandin agonists and use thereof |
| CA2502914A1 (en) | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | 2-pyrrolidones as ep4 receptor agonists |
| US7256211B1 (en) | 2003-01-21 | 2007-08-14 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivatives and medical use thereof |
| EP1603874B1 (en) * | 2003-03-03 | 2008-05-07 | Laboratoires Serono SA | G-lactam derivatives as prostaglandin agonists |
| US7169807B2 (en) | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| WO2006016695A1 (ja) | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤 |
| EP1782830A4 (en) | 2004-08-10 | 2009-07-29 | Ono Pharmaceutical Co | PREVENTION AND / OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING AN EP4 AGONIST |
| BRPI0611079A2 (pt) * | 2005-06-03 | 2010-08-03 | Ono Pharmaceutical Co | agentes para a regeneração e/ou proteção de nervos |
| US20070232660A1 (en) | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| BRPI0811306A2 (pt) | 2007-05-08 | 2015-01-27 | Nat Univ Corp Hamamatsu | Ativador de célula t citotóxica compreendendo agonista ep4 |
| EP2215084B1 (en) | 2007-10-23 | 2016-09-28 | Allergan, Inc. | Therapeutic substituted lactams |
| US20120270934A1 (en) | 2009-07-03 | 2012-10-25 | Concert Pharmaceuticals, Inc. | Prostacyclin derivatives |
| CN103201261A (zh) | 2010-11-10 | 2013-07-10 | 埃科特莱茵药品有限公司 | 用作为食欲素受体拮抗剂的内酰胺衍生物 |
| US20120283293A1 (en) | 2011-05-06 | 2012-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation |
| TW201321003A (zh) | 2011-08-02 | 2013-06-01 | Ono Pharmaceutical Co | 左心室擴張機能改善劑 |
| CN107802623B (zh) | 2012-07-19 | 2020-10-30 | 开曼化学股份有限公司 | 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物 |
-
2014
- 2014-03-14 ES ES14729106.6T patent/ES2635635T3/es active Active
- 2014-03-14 CA CA2906134A patent/CA2906134A1/en active Pending
- 2014-03-14 JP JP2016502973A patent/JP6317807B2/ja active Active
- 2014-03-14 SG SG11201507470WA patent/SG11201507470WA/en unknown
- 2014-03-14 EP EP14729106.6A patent/EP2989098B1/en active Active
- 2014-03-14 EA EA201591793A patent/EA201591793A1/ru unknown
- 2014-03-14 WO PCT/US2014/029057 patent/WO2014144584A2/en active Application Filing
- 2014-03-14 US US14/775,427 patent/US9688627B2/en active Active
- 2014-03-14 PT PT147291066T patent/PT2989098T/pt unknown
- 2014-03-14 EP EP17169751.9A patent/EP3235817B1/en not_active Not-in-force
- 2014-03-14 AU AU2014228973A patent/AU2014228973B2/en not_active Expired - Fee Related
- 2014-03-14 DK DK14729106.6T patent/DK2989098T3/en active
- 2014-03-14 CN CN201480015554.7A patent/CN105143217A/zh active Pending
- 2014-03-14 BR BR112015023080A patent/BR112015023080A2/pt not_active IP Right Cessation
- 2014-03-14 KR KR1020157026225A patent/KR20150130326A/ko not_active Application Discontinuation
-
2015
- 2015-09-01 IL IL240988A patent/IL240988A/en active IP Right Grant
- 2015-09-15 PH PH12015502165A patent/PH12015502165A1/en unknown
-
2016
- 2016-08-29 HK HK16110267.7A patent/HK1222170A1/zh unknown
-
2017
- 2017-01-12 IL IL250077A patent/IL250077A0/en unknown
- 2017-06-01 JP JP2017109178A patent/JP6352497B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA201591793A1 (ru) | 2016-01-29 |
| IL240988A (en) | 2017-05-29 |
| JP2016516050A (ja) | 2016-06-02 |
| DK2989098T3 (en) | 2017-08-28 |
| US9688627B2 (en) | 2017-06-27 |
| EP3235817A1 (en) | 2017-10-25 |
| WO2014144584A3 (en) | 2014-11-20 |
| IL240988A0 (en) | 2015-11-30 |
| IL250077A0 (en) | 2017-03-30 |
| KR20150130326A (ko) | 2015-11-23 |
| CA2906134A1 (en) | 2014-09-18 |
| HK1222170A1 (zh) | 2017-06-23 |
| JP6317807B2 (ja) | 2018-04-25 |
| EP2989098A2 (en) | 2016-03-02 |
| EP3235817B1 (en) | 2018-12-12 |
| BR112015023080A2 (pt) | 2017-07-18 |
| CN105143217A (zh) | 2015-12-09 |
| ES2635635T3 (es) | 2017-10-04 |
| PH12015502165A1 (en) | 2016-01-25 |
| AU2014228973A1 (en) | 2015-09-17 |
| JP6352497B2 (ja) | 2018-07-04 |
| PT2989098T (pt) | 2017-08-16 |
| JP2017186356A (ja) | 2017-10-12 |
| EP2989098B1 (en) | 2017-05-10 |
| AU2014228973B2 (en) | 2018-11-08 |
| US20160060216A1 (en) | 2016-03-03 |
| WO2014144584A2 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202012656WA (en) | Heterocyclic compounds useful in the treatment of disease | |
| HK1216251A1 (zh) | 吡唑並吡咯烷衍生物及其治病作用 | |
| PL3811943T3 (pl) | Związek do stosowania w leczeniu zaburzeń oczu | |
| GB2513167B (en) | Tetrahydrocannabivarin for use in the treatment of nausea and vomiting | |
| EP2991649A4 (en) | COMPOSITIONS AND METHODS FOR TREATING STATES AND PSYCHIC DISEASES RELATED TO MICROBIOTA | |
| HK1222398A1 (zh) | 治療伯克霍爾德氏菌感染症的組合物及方法 | |
| GB201320723D0 (en) | Composition and methods of treatment | |
| PL3004108T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób | |
| IL236637A (en) | Diploorulctam Compounds as selective ep4 receptor agonists for use in ep4-mediated diseases and conditions | |
| SG11201509782TA (en) | Compositions and methods for the treatment of diabetes and pre-diabetes | |
| IL250077A0 (en) | Lactam compounds as selective agonists for the ep4 receptor for use in the treatment of ep4-mediated diseases and conditions | |
| HK1224184A1 (zh) | 用於治療炎性疾病的化合物、藥物組合物和方法 | |
| PL3466425T3 (pl) | Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych | |
| HK1220374A1 (zh) | 用於治療碳氧血紅蛋白血症的組合物和方法 | |
| HK1214511A1 (zh) | 鹽酸蘭地洛爾在快速性心律失常的長期治療中的用途 | |
| EP2941248A4 (en) | COMPOSITION AND METHOD FOR TREATING BODY SURFACE | |
| AP2015008849A0 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |